FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129192144> ?p ?o ?g. }

• W3129192144 endingPage "146" @default.
• W3129192144 startingPage "143" @default.
• W3129192144 abstract "Introduction. The presence of a germinal BRCA mutation occurs in 3–4% of all breast cancer (BC) patients with various biological subtypes, but significantly with a high frequency in patients with a triple negative biological subtype (in 10–20% of cases). For the treatment of patients with HER2-negative metastatic breast cancer associated with gBRCA mutation, the effectiveness of biologically targeted drugs from the group of PARP inhibitors (olaparib and talazoparib) has been proven. P urpose. Comparison of the results of our experience with the use of talazoparib in patients with HER2-gBRCA+ + mBC with the data of the EMBRACA registration study. Mat erials and methods. As part of the multicenter compassionate use program (CUP) with the support of Pfizer, 24 patients with HER2-negative metastatic gBRCA-associated mutation metastatic breast cancer (HER2-gBRCA+ breast cancer) received biologically targeted therapy with the PARP inhibitor talazoparib at a standard oral dose of 1 mg per day for vital indications . The average age of patients with HER2-gBRCAm+ breast cancer was 50 years (29–90 years). Results. Objective response (OR) was registered in 29% of cases, disease control (OR+stabilization) – in 71% of cases. The median progression-free survival (PFS) was 6.5 months (95% CI [3–10]). Objective response, disease control, and median PFS were evaluated depending on the biological subtype, the number of lines of previous therapy, and the presence of platinum-containing agents in the anamnesis. Objective response and disease control were evaluated depending on the biological subtype: in patients with ER+HER2-mBC versus patients with triple negative subtype, OR was 33% vs 22%, and disease control was 83% vs 61%, respectively. In the presence of < 3 vs ≥ 3 lines of therapy for metastatic disease in the anamnesis, OR was 31% vs 12.5%, disease control – 75% vs 50% of cases, respectively. In the presence or absence of platinum-containing agents in the anamnesis, OR was observed in 22% vs 33% of cases, and disease control – 67% vs 67%, respectively. In patients with the luminal subtype versus patients with the triple negative subtype, the PFS was 9 months vs 5 months, respectively (HR = 0.705; 95% CI [0.231–2.147]; p = 0.5208). Median PFS in the presence of <3 vs ≥3 lines of therapy for metastatic disease in the anamnesis was 9 months vs 4 months, respectively (HR = 4,216; 95% CI [1,334–13,327]; p = 0.0056). In the presence or absence of platinum-containing agents in previous lines of therapy 5 months vs 9.5 months, respectively (HR =1.484; 95% CI [0.48–4.582]; p = 0.4750). During the treatment with talazoparib adverse events of the 3rd-4th grades were observed in 5 patients (20,8%). These include moderate and severe anemia in 3 patients (12.5%), thrombocytopenia in 1 patient (4%), and neutropenia in 1 patient (4%). The majority of patients (79,5%), which received talazoparib, did not require dose adjustment. The need to reduce the dose to 0.75 mg was noted in 3 patients (12.5%), to 0.5 mg – in 2 patients (8%). Hemotransfusion was performed in 3 patients. For effective therapy safety management regular monitoring of blood parameters is necessary. Conclusion. Thus, targeted therapy with talazoparib is an effective treatment option for HER2-gBRCA+ mBC." @default.
• W3129192144 created "2021-02-15" @default.
• W3129192144 creator A5008962389 @default.
• W3129192144 creator A5011506167 @default.
• W3129192144 creator A5021279830 @default.
• W3129192144 creator A5027216763 @default.
• W3129192144 creator A5036016408 @default.
• W3129192144 creator A5036477674 @default.
• W3129192144 creator A5036692508 @default.
• W3129192144 creator A5039442456 @default.
• W3129192144 creator A5045489136 @default.
• W3129192144 creator A5046042894 @default.
• W3129192144 creator A5046366890 @default.
• W3129192144 creator A5049175689 @default.
• W3129192144 creator A5057430891 @default.
• W3129192144 creator A5059123275 @default.
• W3129192144 creator A5061479173 @default.
• W3129192144 creator A5061555782 @default.
• W3129192144 creator A5065211019 @default.
• W3129192144 creator A5065669023 @default.
• W3129192144 creator A5074161568 @default.
• W3129192144 creator A5081523614 @default.
• W3129192144 creator A5084608680 @default.
• W3129192144 creator A5089395526 @default.
• W3129192144 creator A5090629533 @default.
• W3129192144 date "2020-12-21" @default.
• W3129192144 modified "2023-10-06" @default.
• W3129192144 title "Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer" @default.
• W3129192144 cites W1984629445 @default.
• W3129192144 cites W1989006164 @default.
• W3129192144 cites W2597062310 @default.
• W3129192144 cites W2621271973 @default.
• W3129192144 cites W2886477543 @default.
• W3129192144 cites W3014383023 @default.
• W3129192144 cites W3030475138 @default.
• W3129192144 cites W3048202530 @default.
• W3129192144 doi "https://doi.org/10.21518/2079-701x-2020-20-143-149" @default.
• W3129192144 hasPublicationYear "2020" @default.
• W3129192144 type Work @default.
• W3129192144 sameAs 3129192144 @default.
• W3129192144 citedByCount "1" @default.
• W3129192144 countsByYear W31291921442022 @default.
• W3129192144 crossrefType "journal-article" @default.
• W3129192144 hasAuthorship W3129192144A5008962389 @default.
• W3129192144 hasAuthorship W3129192144A5011506167 @default.
• W3129192144 hasAuthorship W3129192144A5021279830 @default.
• W3129192144 hasAuthorship W3129192144A5027216763 @default.
• W3129192144 hasAuthorship W3129192144A5036016408 @default.
• W3129192144 hasAuthorship W3129192144A5036477674 @default.
• W3129192144 hasAuthorship W3129192144A5036692508 @default.
• W3129192144 hasAuthorship W3129192144A5039442456 @default.
• W3129192144 hasAuthorship W3129192144A5045489136 @default.
• W3129192144 hasAuthorship W3129192144A5046042894 @default.
• W3129192144 hasAuthorship W3129192144A5046366890 @default.
• W3129192144 hasAuthorship W3129192144A5049175689 @default.
• W3129192144 hasAuthorship W3129192144A5057430891 @default.
• W3129192144 hasAuthorship W3129192144A5059123275 @default.
• W3129192144 hasAuthorship W3129192144A5061479173 @default.
• W3129192144 hasAuthorship W3129192144A5061555782 @default.
• W3129192144 hasAuthorship W3129192144A5065211019 @default.
• W3129192144 hasAuthorship W3129192144A5065669023 @default.
• W3129192144 hasAuthorship W3129192144A5074161568 @default.
• W3129192144 hasAuthorship W3129192144A5081523614 @default.
• W3129192144 hasAuthorship W3129192144A5084608680 @default.
• W3129192144 hasAuthorship W3129192144A5089395526 @default.
• W3129192144 hasAuthorship W3129192144A5090629533 @default.
• W3129192144 hasBestOaLocation W31291921441 @default.
• W3129192144 hasConcept C104317684 @default.
• W3129192144 hasConcept C121608353 @default.
• W3129192144 hasConcept C126322002 @default.
• W3129192144 hasConcept C143998085 @default.
• W3129192144 hasConcept C182979987 @default.
• W3129192144 hasConcept C2775930923 @default.
• W3129192144 hasConcept C2779138821 @default.
• W3129192144 hasConcept C2779962180 @default.
• W3129192144 hasConcept C2780194787 @default.
• W3129192144 hasConcept C530470458 @default.
• W3129192144 hasConcept C55493867 @default.
• W3129192144 hasConcept C71924100 @default.
• W3129192144 hasConcept C82381507 @default.
• W3129192144 hasConcept C86803240 @default.
• W3129192144 hasConceptScore W3129192144C104317684 @default.
• W3129192144 hasConceptScore W3129192144C121608353 @default.
• W3129192144 hasConceptScore W3129192144C126322002 @default.
• W3129192144 hasConceptScore W3129192144C143998085 @default.
• W3129192144 hasConceptScore W3129192144C182979987 @default.
• W3129192144 hasConceptScore W3129192144C2775930923 @default.
• W3129192144 hasConceptScore W3129192144C2779138821 @default.
• W3129192144 hasConceptScore W3129192144C2779962180 @default.
• W3129192144 hasConceptScore W3129192144C2780194787 @default.
• W3129192144 hasConceptScore W3129192144C530470458 @default.
• W3129192144 hasConceptScore W3129192144C55493867 @default.
• W3129192144 hasConceptScore W3129192144C71924100 @default.
• W3129192144 hasConceptScore W3129192144C82381507 @default.
• W3129192144 hasConceptScore W3129192144C86803240 @default.
• W3129192144 hasIssue "20" @default.
• W3129192144 hasLocation W31291921441 @default.
• W3129192144 hasLocation W31291921442 @default.

• next